Stereospecific binding of timolol, a beta-adrenergic blocking agent

Area of Science:

• Pharmacology
• Biochemistry
• Neuroscience

Background:

• Beta-adrenergic blocking agents are crucial in cardiovascular and neurological treatments.
• Understanding the binding characteristics of drugs like timolol is essential for optimizing therapeutic efficacy.
• Stereospecificity in drug-receptor interactions can significantly influence pharmacological effects.

Purpose of the Study:

• To investigate the stereospecific binding of timolol in particulate fractions of rat heart, lungs, and brain.
• To compare the binding kinetics and tissue distribution of the l- and d-isomers of timolol.
• To identify potential beta-adrenoreceptors involved in timolol's action through competitive binding studies.

Main Methods:

• Radioligand binding assays using 14C-timolol.
• Administration of varying doses of timolol and its isomers to rats.
• Measurement of drug concentrations in tissue particulate fractions over time.
• Competitive inhibition studies with other beta-adrenergic blocking agents.

Main Results:

• Timolol bound to both stereospecific and nonspecific sites in heart, lung, and brain tissues.
• The d-isomer of timolol exclusively bound to nonspecific sites.
• The l-isomer of timolol showed significantly slower dissociation rates and higher tissue concentrations compared to the d-isomer.
• Intravenous timolol and l-propranolol, but not their d-forms, inhibited 14C-timolol binding in a dose-dependent manner.
• Specific beta-blockers like racemic timolol, propranolol, bunolol, and bunitrolol competed effectively for binding sites, while practolol, sotalol, and butoxamine did not.

Conclusions:

• The stereospecific binding of timolol, particularly its l-isomer, is a key characteristic influencing its distribution and retention in tissues.
• These stereospecific binding sites are likely associated with beta-adrenoreceptors.
• The findings support the hypothesis that stereoselectivity plays a significant role in the pharmacological activity of beta-adrenergic blocking agents.